Rhinomed (CHIA:RNO) - Stock Price, News & Analysis

RNO Stock Overview

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide.

RNO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap (A$12M)

Earnings have declined by 8.2% per year over past 5 years

Negative shareholders equity

Rhinomed Limited Competitors

Althea Group Holdings

ASX:AGH

AU$12.3m

Avecho Biotechnology

ASX:AVE

AU$12.7m

AusCann Group Holdings

ASX:AC8

AU$17.6m

Firebrick Pharma

ASX:FRE

AU$12.2m

Price History & Performance

Summary of all time highs, changes and price drops for Rhinomed
Historical stock prices
Current Share Price	AU$0.04
52 Week High	AU$0.10
52 Week Low	AU$0.019
Beta	0.88
1 Month Change	42.86%
3 Month Change	n/a
1 Year Change	-55.56%
3 Year Change	-68.00%
5 Year Change	-74.19%
Change since IPO	-82.61%

Recent updates

Shareholder Returns

	RNO	AU Pharmaceuticals	AU Market
7D	0%	10.6%	0.7%
1Y	-55.6%	43.6%	6.3%

Return vs Industry: RNO underperformed the Australian Pharmaceuticals industry which returned 59.7% over the past year.

Return vs Market: RNO underperformed the Australian Market which returned 4.4% over the past year.

Price Volatility

Is RNO's price volatile compared to industry and market?
RNO volatility
RNO Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.2%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: RNO's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine RNO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2004	n/a	Michael Johnson	www.rhinomed.global

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. The company offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. Its products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab.

Rhinomed Limited Fundamentals Summary

How do Rhinomed's earnings and revenue compare to its market cap?
RNO fundamental statistics
Market cap	AU$11.51m
Earnings (TTM)	-AU$10.91m
Revenue (TTM)	AU$8.05m

1.4x

P/S Ratio

-1.1x

P/E Ratio

Is RNO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RNO income statement (TTM)
Revenue	AU$8.05m
Cost of Revenue	AU$2.78m
Gross Profit	AU$5.28m
Other Expenses	AU$16.18m
Earnings	-AU$10.91m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.038
Gross Margin	65.53%
Net Profit Margin	-135.49%
Debt/Equity Ratio	-90.4%

How did RNO perform over the long term?

See historical performance and comparison

RNO Stock Overview

Rewards

Risk Analysis

Rhinomed Limited Competitors

ASX:AGH

AU$12.3m

ASX:AVE

AU$12.7m

ASX:AC8

AU$17.6m

ASX:FRE

AU$12.2m

Price History & Performance

Recent News & Updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Less than half of directors are independent

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Less than half of directors are independent

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Less than half of directors are independent

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Less than half of directors are independent

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Less than half of directors are independent

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

Less than half of directors are independent

New major risk - Market cap size

Less than half of directors are independent

Insider recently bought AU$242k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Insider recently bought AU$372k worth of stock

Less than half of directors are independent

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

Shareholder Returns

Price Volatility

About the Company

Rhinomed Limited Fundamentals Summary

1.4x

-1.1x

Earnings & Revenue